[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Nove de Julho\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":632},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,42,74,94,113,136,173,195,223,250,272,296,321,348,372,398,421,441,467,492,516,536,565,591,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100616176","efficacy-of-aerobic-exercise-versus-therapeutic-exercises-on-exercise-induced-hypoalgesia-in-knee-osteoarthritis-100616176",false,"NCT07302204","Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis","Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis. Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical diagnosis of symptomatic knee osteoarthritis for at least 3 months.\n* Report of knee pain for more than 3 months and average knee pain intensity ≥ 3 on the 0 to 10 Numeric Rating Scale.\n* Morning stiffness lasting less than 30 minutes.\n* Clinical signs compatible with knee osteoarthritis. crepitus, bony tenderness and absence of palpable warmth at the knee.\n* Altered exercise-induced hypoalgesia: absence of exercise-induced hypoalgesia and hyperalgesic response to exercise.\n\nExclusion Criteria:\n\n* Signs and symptoms indicating the hip as the main source of pain.\n* Osteoporosis\n* Fibromyalgia\n* History of tumors or cancer\n* Active inflammatory joint diseases, such as rheumatoid arthritis or gout.\n* Previous arthroplasty of any lower limb joint.\n* Neurological diseases, including Parkinson's disease, stroke, multiple sclerosis, muscular dystrophy, motor neuron disease or Alzheimer's disease.\n* Cardiovascular diseases for which exercise is formally contraindicated.\n* Infected wounds or osteomyelitis in the knee region.\n* Deep vein thrombosis or thrombophlebitis.\n* Sensory alterations in the lower limbs.\n* Cognitive or cardiopulmonary impairments that limit safe participation in the exercise program.\n* Use of walking aids.\n* Recent knee trauma.","ALL","40 Years","75 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study compares two exercise strategies in people with knee osteoarthritis. The first is aerobic exercise on a recumbent cycle ergometer, with effort controlled by the Borg scale. The second is a therapeutic exercise program with resistance, neuromuscular, mobility, and balance components. The primary objective is to determine which approach produces greater exercise induced hypoalgesia, measured by the increase in pressure pain threshold at the knee within the session across four anchor sessions during a ten week program. This is a randomized clinical trial with two parallel arms. Ninety participants, between forty five and seventy five years of age, will be allocated to one of the two groups. Allocation sequence concealment will be ensured using opaque envelopes. The outcome assessor will remain blinded to group allocation. The interventions will take place three times per week for ten weeks. Assessments will be performed at baseline and after ten weeks. Within session measurements will also be taken in weeks one, four, seven, and ten. The primary outcome is the intra session change in pressure pain threshold at the medial compartment of the knee. Secondary outcomes include exercise induced hypoalgesia in the quadriceps and trapezius, chronic adaptation of pressure pain threshold, conditioned pain modulation, pain intensity, pain self efficacy, knee related health status, functional performance, quadriceps strength, global perceived effect, and adherence. The planned sample size is forty five participants per group. The analysis will follow the intention to treat principle. The primary outcome will be compared using linear mixed models with group and time effects. Clinical outcomes at T1 will be adjusted for baseline values. Estimates, confidence intervals, and interpretation in light of minimally important differences will be reported.",[28],"Osteoarthritis of the Knee","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2026-02-20",{"date":37,"type":22},"2029-12-20",{"name":39,"class":40},"University of Nove de Julho","OTHER",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100639872","chronic-effects-of-photobiomodulation-with-an-led-vest-on-functional-capacity-inflammatory-markers-and-muscle-perfusion-in-children-with-asthma-100639872","NCT07613671","Chronic Effects of Photobiomodulation With an LED Vest on Functional Capacity, Inflammatory Markers, and Muscle Perfusion in Children With Asthma","Asthma PBM","Critérios de Inclusão: Crianças em idade escolar de 6 a 17 anos Diagnosticado com asma leve a moderada (tratamento farmacológico regular) clinicamente estável Critérios de exclusão:Histórico de exacerbação da asma dentro de 30 dias antes do início do estudo, FAlha no preenchimento dos questionários","6 Years","17 Years",{"count":52,"type":22},60,[25],"Asthma is a chronic inflammatory disease of the airways that results in tissue remodeling, airflow limitation, and bronchial hyperresponsiveness. This study aims to evaluate the long-term effects of photobiomodulation using an LED vest in the management of pediatric asthma. It is a randomized clinical trial involving children aged 6 to 17 years diagnosed with mild to moderate asthma, divided into two groups: an intervention group (using a vest with active LEDs) and a control group (using the vest turned off, simulating the intervention without light emission). The methodology includes clinical and functional assessments such as spirometry, the Asthma Control Test (ACT), the GINA questionnaire, and the Incremental Step Test (IST), which measures exercise tolerance. Photobiomodulation through LEDs promotes cellular biostimulation without thermal effects, modulating inflammatory processes and optimizing tissue regeneration. It is expected that the LED vest will contribute to improving pulmonary function, enhancing quality of life, and complementing conventional treatments. This project aims to advance the clinical application of photobiomodulation as an accessible and effective therapeutic alternative for pediatric asthma.",[56],"Asthma (Diagnosis)",[58,59,60,61,62,63],"pediatric asthma","Photobiomodulation Therapy","Pulmonary Function","Inflammatory Biomarkers","Low-Level Light Therapy (LLLT)","asthma","NOT_YET_RECRUITING","2026-05-28",{"date":67,"type":33},"2026-06-02",{"date":69,"type":22},"2026-07-30",{"date":71,"type":22},"2028-01-30",{"name":39,"class":40},1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":73},"100573265","effects-of-including-interferential-current-in-a-therapeutic-exercise-program-in-individuals-with-knee-osteoarthritis-100573265","NCT06744036","Effects of Including Interferential Current in a Therapeutic Exercise Program in Individuals With Knee Osteoarthritis","Inclusion Criteria:\n\n* both sexes\n* between 40 years old and 75 years old\n* with a clinical diagnosis of unilateral KOA\n* Who has had knee pain for more than 3 months\n* With a minimum score of 3 points on the numerical pain scale\n* Morning stiffness for less than 30 minutes\n* Crepitus\n* Bone tenderness and absence of palpable heat\n\nExclusion Criteria:\n\n* Hip OA\n* Severe osteoporosis\n* Fibromyalgia\n* Clinical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any joint replacement in the lower extremity\n* Neurological diseases (Parkinson's disease, stroke\n* Multiple sclerosis\n* muscular dystrophies\n* Diseases involving motor neurons\n* Alzheimer's disease\n* Infected wounds or osteomyelitis in the knee region\n* Deep vein thrombosis or thrombophlebitis\n* Sensory alteration in the lower limbs\n* Cognitive and cardiopulmonary impairment that may prevent or limit the execution of exercises\n* Use of a walking assistance device\n* History of recent knee trauma\n* Having undergone any form of treatment involving physical therapy\n* intra-articular corticosteroids\n* anti-inflammatory drugs\n* opioid medication or chondroprotective in the six months before the start of the interventions",{"count":81,"type":22},138,[25],"The first-line treatment for knee osteoarthritis (KOA) in terms of pain and functionality is physical exercise. The use of interferential current (IC) associated with other resources may be beneficial in reducing pain intensity and improving functionality. However, the effects of its simultaneous use with therapeutic exercise have not yet been fully established. The aim of this project will be to evaluate the effects of including IC in a therapeutic exercise program in relation to pain intensity, functionality, self-efficacy, maximum voluntary contraction and overall perceived effect in individuals with KOA. Therefore, research participants of both sexes, between 40 and 75 years old, with a clinical diagnosis of unilateral KOA, who have knee pain for more than 3 months, with a minimum score of 3 points on the numerical pain scale, morning stiffness for less than 30 minutes, crepitation, bone sensitivity, and absence of palpable heat will be recruited. The research participants will be randomized into three groups: therapeutic exercises (n=46) and therapeutic exercises + IC (n=46) and therapeutic exercises + IC placebo (n=46). Eight consecutive weeks of treatment will be carried out. The research participants will be evaluated before the intervention, after the end of the intervention of eight consecutive weeks of intervention and after four weeks at the end of the last week of intervention, through the instruments: numeric pain scale (NPS), Knee Injury and Osteoarthritis Outcome Score (KOOS), patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), maximum voluntary isometric contraction (MVIC), 30-second sit-to-stand test (TSL30s), global perception scale (EPG). For data analysis, a normality test will be used to verify the distribution of the data and a statistical test appropriate for the appropriate intra and inter-group comparisons, thus considering two factors in the comparisons, time and group. A significance level of 5% will be adopted.",[85],"Osteoarthritis, Knee","2026-05-21",{"date":88,"type":33},"2026-05-22",{"date":90,"type":33},"2025-01-20",{"date":92,"type":22},"2026-07-28",{"name":39,"class":40},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":73},"100530458","effects-of-including-a-chronic-pain-neuroscience-education-program-for-individuals-with-knee-oa-100530458","NCT06187038","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA: Randomized, Blinded Clinical Trial","Inclusion Criteria:\n\n* A clinical diagnosis of knee osteoarthritis (knee pain for \\> 3 months\n* Morning stiffness \\\u003C30 minutes\n* Crepitus\n* Bone tenderness, and absence of palpable heat and\u002For diagnosis established radiographically (determined by Kellgren and Lawrence grade 1 to 3 on a scale 1 up to 4)\n\nExclusion Criteria:\n\n* Hip OA\n* severe osteoporosis\n* Fibromyalgia\n* Medical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any lower extremity joint replacement\n* Neurological diseases (Parkinson's disease, stroke, Multiple Sclerosis, muscular dystrophy, motor neuron disease, Alzheimer's disease, cognitive and cardiopulmonary impairment that may prevent or limit the performance of exercises, use of a gait assistance device, history of recent knee trauma.\n* Having undergone any form of treatment involving physiotherapy, intra-articular corticosteroids, anti-inflammatories or chondroprotective in the last six months","80 Years",{"count":103,"type":22},92,[25],"Research participants diagnosed with knee osteoarthritis will be randomized through a draw using sealed opaque envelopes indicating two groups: 1. therapeutic exercises, 2. therapeutic exercises + chronic pain neuroscience education program. The primary outcome will be functional performance using a patient-reported measure, the Knee Injury and Osteoarthritis Outcome Score (KOOS).\n\nThe selected secondary outcomes will be pain intensity by the numerical pain scale (END), physical function reported by the patient by the patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), functional mobility by the timed up and test (TUG), general effect perceived through the global perception scale (EPG), muscle strength through Maximum Voluntary Isometric Contraction (MVIC) and functionality and disability through the World Health Organization Disability Assessment Schedule (WHODAS).",[85],{"date":88,"type":33},{"date":109,"type":33},"2024-05-28",{"date":111,"type":22},"2026-12-15",{"name":39,"class":40},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":17,"minAge":49,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":73},"100592866","longitudinal-evaluation-of-minimally-invasive-protocols-for-dental-caries-in-brazilian-schoolchildren-100592866","NCT06999005","Longitudinal Evaluation of Minimally Invasive Protocols for Dental Caries in Brazilian Schoolchildren","Longitudinal Evaluation of Minimally Invasive Protocols for the Prevention and Control of Dental Caries in Brazilian Schoolchildren: A Multicenter Study Protocol","Inclusion Criteria:\n\n* Children aged between 6 and 12 years at the time of enrollment\n* Presence of at least one erupted permanent first molar\n* Diagnosis of active caries lesions classified according to ICDAS (scores 1 to 6)\n* Written informed consent signed by a legal guardian and assent signed by the child\n* Ability to attend quarterly follow-up visits over a 24-month period\n\nExclusion Criteria:\n\n* Children requiring endodontic treatment or presenting extensive pulpal involvement\n* Presence of systemic diseases or medical conditions that contraindicate dental care\n* Known allergy to any material used in the study (fluoride varnish, high-viscosity glass ionomer cement)\n* Participation in other clinical dental studies that could interfere with the outcomes",true,"12 Years",{"count":123,"type":22},2500,[25],"This multicenter longitudinal interventional study aims to evaluate minimally invasive protocols for the prevention and control of dental caries in Brazilian schoolchildren under routine public health conditions. In the first phase, 50,000 children aged 6 to 12 years from public schools in five Brazilian cities will undergo dental screening using ICDAS criteria and receive preventive and educational oral health measures. In the longitudinal treatment phase, 2,500 children diagnosed with active carious lesions will be managed according to ICDAS-based minimally invasive treatment protocols. Participants will be followed every three months for up to 24 months.",[127],"Dental Caries","2026-05-12",{"date":130,"type":33},"2026-05-15",{"date":132,"type":33},"2026-02-28",{"date":134,"type":22},"2028-12",{"name":39,"class":40},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":158,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":73},"100602421","effect-of-photobiomodulation-on-healing-of-venous-leg-ulcers-100602421","NCT07123285","Effect of Photobiomodulation on Healing of Venous Leg Ulcers","Effect of Photobiomodulation on the Healing of Venous Ulcers in the Lower Limbs","Inclusion Criteria:\n\n* Patients of both sexes;\n* Individuals with venous ulcers in the lower limbs for at least three weeks that have not healed;\n* Age between 18 and 85 years;\n* Residents of Lençóis Paulista or nearby regions.\n\nExclusion Criteria:\n\n* Patients with ulcers of non-venous etiology;\n* Pregnant women;\n* Presence of severe arterial disease in the lower limbs.","18 Years","85 Years",{"count":146,"type":22},96,[25],"This randomized, controlled, double-blind clinical trial will evaluate the efficacy of photobiomodulation (PBM) combined with compression therapy in the healing of venous ulcers (VUs) in the lower limbs. A total of 96 participants will be allocated into two groups: Experimental Group (PBM + compression) and Control Group (sham PBM + compression). Treatments will be administered twice weekly for 16 weeks (32 sessions). The primary outcome will be complete wound healing. Secondary outcomes include changes in ulcer area and volume, pain (VAS), quality of life (SF-36), clinical severity (VCSS), wound quality (Bates-Jensen Scale), infrared thermography, and treatment costs. Data will be analyzed using ANOVA or Kruskal-Wallis, chi-square or Fisher's exact test, and Kaplan-Meier survival analysis, with a significance level of p \\\u003C 0.05.",[150,151,152,153,154,155,156,157],"Venous Disease","Venous Insufficiency (Chronic)(Peripheral)","Venous Insufficiency of Leg","Venous Leg Ulcer (VLU)","Venous Leg Ulcer","Venous Hypertension Ulcers","Varicose Ulcers","Varicose Ulcer of Lower Limb",[159,160,161,162,163,164],"venous ulcers","varicose ulcers","photobiomodulation","lasers","phototherapy","venous leg ulcer","2026-04-27",{"date":167,"type":33},"2026-04-29",{"date":169,"type":22},"2026-05",{"date":171,"type":22},"2027-07",{"name":39,"class":40},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":41},"100336696","handgrip-training-in-patients-with-peripheral-artery-disease-100336696","NCT03663777","Handgrip Training in Patients With Peripheral Artery Disease","Effects of 12 Weeks of Isometric Handgrip Training in Blood Pressure in Patients With Peripheral Artery Disease","Isopress_03","Inclusion Criteria:\n\n* Women in post-menopause phase without hormone replacement therapy\n* Ankle-brachial index \\\u003C0.90\n* Not severe obese (≥ 35kg\u002Fm2)\n* Not present amputation in the limbs\n* Have blood pressure levels lower than 160mmHg for systolic and 105mmHg for diastolic\n\nExclusion Criteria:\n\n* patients will only be excluded if they make any medication changes before completing the intervention period or present any health problems that prevent physical activity.","45 Years",{"count":183,"type":22},30,[25],"The aim of this study is to analyze the effects of isometric handgrip training (IHT) on blood pressure of hypertensive patients with peripheral arterial disease. Will be recruited 30 patients which will be randomized into 2 groups (15 per group), IHT and control group (CG). IHT group will training isometric contraction for 12 weeks. In CG patients will be encouraged to increase the level of physical activity. In the pre and post-intervention cardiovascular measures will be obtained.",[187],"Peripheral Arterial Disease",{"date":189,"type":33},"2026-05-01",{"date":191,"type":33},"2018-08-01",{"date":193,"type":22},"2027-12-30",{"name":39,"class":40},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":120,"sex":202,"minAge":181,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":73},"100583257","eryag-laser-combined-with-vaginal-estriol-for-genitourinary-syndrome-of-menopause-100583257","NCT06873971","Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause","Effects of Erbium:YAG Laser Combined With Vaginal Estriol Therapy in Postmenopausal Women With Genitourinary Syndrome of Menopause: A Protocol for a Randomised, Double-blind Controlled Trial","Inclusion criteria\n\n* Postmenopausal women (45-70 years of age).\n* At least one of moderate symptom of GSM (vaginal dryness, burning sensation, dyspareunia, and persistent leukorrhea), defined by ≥ 4 on Visual Analog Scale (VAS) ranging from 0 to 10.\n* Vaginal pH ≥5.0 at baseline assessment.\n* Not having undergone hormone replacement therapy (vaginal or systemic) in the previous six months.\n* No use of vaginal moisturizers in the previous 30 days.\n* Demonstrated capacity and willingness to provide written informed consent and adhere to study protocols.\n\nExclusion criteria\n\n* Vaginal or vulvar energy-based interventions (e.g., laser, radiofrequency) in the previous six months.\n* Abnormal cervical cytology, specifically ASCUS, LSIL, or HSIL, documented in the previous six months.\n* Systemic corticosteroid therapy administered in the previous 90 days.\n* Body mass index (BMI) ≥35 kg\u002Fm².\n* Presence of abnormal uterine bleeding in the previous 30 days.\n* History of vaginal surgery in the previous 180 days or grade II or higher uterine prolapse (POP-q).\n* History of malignant neoplasms or exposure to vaginal radiotherapy.\n* Diagnosis of severe liver or kidney disease, autoimmune disease, or severe psychiatric disorder.","FEMALE","70 Years",{"count":52,"type":22},[25],"Chronic hypoestrogenism in postmenopausal women significantly impacts the urogenital epithelium, leading to Genitourinary Syndrome of Menopause (GSM) and increasing susceptibility to gynecological infections due to vaginal pH elevation. Therapies using the Erbium:YAG (Er:YAG) 2940nm laser and low dose topical estrogen have demonstrated efficacy in improving vaginal trophism and restoring microbiota balance.\n\nThis randomised, double-blind clinical study aims to assess the effects of combining Er: YAG laser therapy with vaginal estriol compared with estriol therapy alone in postmenopausal women with GSM. Sixty patients will be recruited and randomly assigned to two groups. All participants will receive low-dose topical estrogen therapy (estriol cream ) for 14 days, followed by twice-weekly applications until completing three laser sessions at four-week intervals. Group 1 (Sham) will receive the laser with minimal fluence (0.5J\u002Fcm²) applied to maintain blinding (auditory cues) below the threshold for biological tissue, while Group 2 , will undergo active laser treatment.\n\nInclusion criteria include age 45-70 years, vaginal pH ≥5, absence of hormone therapy or energy-based intimate treatments for 180 days, and moderate vaginal atrophy symptoms (SCORE \\>4). Exclusion criteria include abnormal cervicalvaginal cytology in the last six months, corticosteroid therapy within 90 days, and BMI ≥35kg\u002Fm².\n\nAssessments will occur at Baseline, 30 days after each laser session and 4 months after the third laser application. The primary outcome is the Vaginal Health Index (VHI), while secondary outcomes include GSM symptom evaluation via the Visual Analog Scale, vaginal microbiota analysis through 16S gene sequencing, and quality-of-life and sexual health questionnaires. Statistical analysis of the groups will be performed using SPSS version 22.0. For analytical statistics, repeated measures ANOVA will be used for continuous data, and non-parametric tests for repeated measures, such as the Friedman test, when appropriate. A p-value \\\u003C0.05 will be considered statistically significant.",[208],"Genitourinary Syndrome of Menopause",[210,211,212,213,214],"Genitourinary syndrome of menopause","postmenopausal women","Erbium: YAG laser","vaginal microbiome","vaginal estriol","2026-04-20",{"date":217,"type":33},"2026-04-23",{"date":219,"type":33},"2025-12-10",{"date":221,"type":22},"2026-12-31",{"name":39,"class":40},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":73},"100550970","effects-of-pbmt-smf-in-mechanically-ventilated-patients-100550970","NCT06454006","Effects of PBMT-sMF in Mechanically Ventilated Patients","Effects of Photobiomodulation Therapy Combined With Static Magnetic Field in Reducing the Number of Days in the Intensive Care Unit (ICU) for Adult Patients Requiring Mechanical Ventilation","Inclusion Criteria:\n\n* Legally authorized representative signed informed consent;\n* Male or female aged 21 years or older;\n* On mechanical ventilation through orotracheal intubation for no more than 72 hours prior to study enrollment or pending mechanical ventilation through orotracheal intubation;\n* Predicted to remain on mechanical ventilation for at least 48 hours (≥48 hours) from the time of study enrollment\n\nExclusion Criteria:\n\n* Mechanical ventilation initiated longer than 72 hours prior to anticipated enrollment;\n* Body Mass Index (BMI) \\> 40 kg\u002Fm²;\n* Fever of 100.4°C or higher;\n* Situated in the prone position for 24 hours or longer during mechanical ventilation;\n* Prognosis of mortality within 72 hours, per the patient's physician;\n* Hypersensitivity to light;\n* Use of non-invasive ventilation, Continuous Positive Airway Pressure (CPAP) and\u002For Bilevel Positive Airway Pressure (BiPAP) device for ≥ 50% of the time over the preceding 6 months;\n* Tracheostomy;\n* Any one or more of the following present on both sides of the neck (bilaterally) at the intended treatment site(s): internal jugular (IJ) venous cannulation; incisions, significant bruising; burn(s); notable skin irritation\u002Frash, or other skin condition that may place the subject at risk from harm from the device treatment;\n* Fracture, external or internal hemorrhage, or at risk of hemorrhage following acute trauma or fracture, or known or potential acute occult bleeding (e.g., gastric ulcer, intestine) in the intended treatment areas;\n* Metallic device implants or body penetrating metallic devices in the upper body\u002Fneck area whose location may interfere with the study device treatment administration. E.g., extracorporeal membrane oxygenation (ECMO) cannula;\n* Non-removable electrical\u002Felectronic device in the upper body\u002Fneck area that may interfere with the study device treatment administration, e.g., -implanted pacemaker or cardiac defibrillator;\n* Cardiogenic or septic shock with ongoing severe hemodynamic instability (according to the American College of Chest Physicians definition (that cannot be stabilized within the 48 hours enrollment period);\n* Conditions that may limit ultrasonographic assessment of diaphragmatic thickness, e.g., occluding chest drain, pleural effusion, pulmonary consolidation of the lower lobe(s);\n* Current cancer of any type;\n* Pregnancy;\n* Any comorbidity, co-existing condition or illness, or other factor that in the opinion of the study investigator may render the subject unsuitable for participation in the study;\n* Admission to the ICU within the last 12 months due to respiratory distress\u002Ffailure;\n* Two or more admissions to the ICU within the prior 12 months for any reason;\n* Current participation in another clinical study.","21 Years",{"count":232,"type":22},112,[25],"The goal of this clinical trial is to evaluate the effectiveness of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in adult patients who require mechanical ventilation. The main questions it aims to answer are:\n\n(i) Does PBMT-sMF lower the length of stay in the intensive care unit (ICU) for mechanically ventilated patients? (ii) Does PBMT-sMF increase the diaphragm thickness in mechanically ventilated patients in the ICU?\n\nResearches will compare active PBMT-sMF plus standard of care to a placebo PBMT-sMF plus standard of care to see if active PBMT-sMF works to prevent or retard disuse atrophy of the diaphragm during mechanical ventilation.",[236],"Respiratory Failure",[238,239,240,241,242,243],"Mechanical ventilation","Photobiomodulation therapy","LLLT","Static magnetic field","Diaphragm","Intensive care unit",{"date":217,"type":33},{"date":246,"type":33},"2024-07-31",{"date":248,"type":22},"2027-06",{"name":39,"class":40},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100634399","disclosing-agents-as-photosensitizers-in-apdt-for-biofilm-control-in-children-100634399","NCT07539181","Disclosing Agents as Photosensitizers in aPDT for Biofilm Control in Children","Disclosing Agents as Photosensitizers in Antimicrobial Photodynamic Therapy for Biofilm Control in Children Aged 3 to 7 Years: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 3 to 7 years\n* Both sexes\n* Good general health status\n* Classified as high caries risk according to the CAMBRA protocol (score ≥ +4 or presence of at least one disease indicator associated with two or more biological risk factors)\n* Written informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* Presence of systemic diseases\n* Use of antibiotics within the last 30 days\n* Use of antimicrobial mouthwash within 48 hours prior to sample collection\n* Presence of structural dental alterations that may interfere with the standardization of the procedure\n* Uncooperative behavior preventing safe clinical examination and intervention","3 Years","7 Years",{"count":260,"type":22},72,[25],"This randomized controlled clinical trial aims to evaluate the effectiveness of plaque disclosing agents used as photosensitizers in antimicrobial photodynamic therapy (aPDT) for the control of dental biofilm in children aged 3 to 7 years. Participants will be allocated into groups to receive different treatment protocols, and biofilm levels will be assessed before and after the interventions. The primary outcome is the reduction of dental biofilm, aiming to determine whether disclosing agents can be an effective alternative photosensitizer in aPDT for pediatric patients.",[264],"Dental Plaque","2026-04-13",{"date":215,"type":33},{"date":268,"type":22},"2026-05-31",{"date":270,"type":22},"2026-08-30",{"name":39,"class":40},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":73},"100633332","photobiomodulation-effects-on-blood-pressure-and-vascular-function-in-treated-hypertensive-patients-100633332","NCT07525310","Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients","Effect of Vascular Photobiomodulation on Cardiovascular Parameters of Treated Hypertensive Patients: A Randomized and Controlled Clinical Trial","Inclusion Criteria:\n\n* Patient in use of losartan at a dose of 100 mg\u002Fday divided into two doses as the only antihypertensive medication, for a minimum of 2 months.\n* Present systolic blood pressure is less than or equal to 140 mmHg and diastolic less than or equal to 90 mmHg.\n* Not having used any other antihypertensive medication in the last 2 months.\n* Age between 18 and 65 years\n* If female, not pregnant\n* No cutaneous\u002Fsubcutaneous lesions on both arms.\n* No musculoskeletal, rheumatic, cardiovascular, metabolic, neurological, oncological, immunological, hematological, psychiatric or cognitive diagnoses and that may be worsened by the intervention or prevent the correct application of FBM vascular.\n\nExclusion Criteria:\n\n* Changes in medication status during the study","65 Years",{"count":281,"type":22},80,[25],"This double-blind, randomized, sham-controlled clinical trial aims to evaluate the effects of vascular photobiomodulation on blood pressure and vascular function in hypertensive patients treated with losartan. A total of 80 patients using losartan (100 mg\u002Fday for at least two months) will be recruited and followed for 4 weeks. Participants will be randomly allocated to either an active photobiomodulation group or a sham control group.",[285],"Hypertension",[287,288,289],"Vascular Photobiomodulation","Blood pressure","Vascular function","2026-04-06",{"date":265,"type":33},{"date":189,"type":22},{"date":294,"type":22},"2027-11-30",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":203,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":73},"100631474","effects-of-physical-training-in-patients-with-advanced-heart-failure-100631474","NCT07501143","Effects of Physical Training in Patients With Advanced Heart Failure","To Evaluate Whether a Rehabilitation Protocol Improves Functional Status and Exercise Tolerance in Hospitalized Patients Awaiting Heart Transplantation While Receiving Positive Inotropic Support. Functional Tests and Scales Will be Used for Assessment. Patients Will Follow an 8-week Rehabilitation Program With Aerobic and Resistance Exercises Distributed Throughout the Week. A New Evaluation Will be Conducted at the End of the Intervention. Keywords: Heart Failure; Heart Transplantation; Physical Exercise","Inclusion Criteria:\n\n* heart failure regardless ; using positive inotropic support regardless of the dose administered, medical prescription to undergo physical therapy.\n\nExclusion Criteria:\n\n* Patients under 18 years of age, atrial and ventricular arrhythmias that cause hemodynamic repercussions, patients with physical and\u002For cognitive limitations non-invasive ventilatory support to carry out the exercise.",{"count":304,"type":22},22,[25],"Heart failure is a condition where the heart cannot pump blood effectively. This can happen due to changes in the heart's structure or function, leading to symptoms like shortness of breath, fatigue, and reduced ability to exercise. These symptoms often worsen the patient's quality of life and increase hospital visits.\n\nExercise is known to help people with heart failure by improving blood flow to the muscles and increasing physical strength. Starting exercise early, even during hospitalization, may help prevent the negative effects of being inactive and improve recovery.\n\nSome patients with advanced heart failure may need a heart transplant. While waiting for a transplant, these patients often receive intravenous medications to support heart function. However, they may become weaker and lose physical capacity during this time.\n\nThis study will test whether a supervised exercise program during hospitalization can help improve physical ability and exercise tolerance in patients with advanced heart failure who are on the heart transplant waiting list and receiving intravenous medication. The goal is to help these patients stay stronger and more stable while they wait for a transplant.",[308,309,310],"Insuficiência Cardíaca","Transplante Cardíaco","Exercício Físico",[312],"Heart Failure, Heart Transplant; Physical Exercise","2026-04-02",{"date":315,"type":33},"2026-04-08",{"date":317,"type":22},"2026-05-30",{"date":319,"type":22},"2029-10-31",{"name":39,"class":40},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":120,"sex":17,"minAge":143,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":73},"100595483","effects-of-red-and-infrared-photobiomodulation-in-rhinoplasty-at-a-single-centre-100595483","NCT07033039","Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","Effects of Photobiomodulation With Red and Infrared Low-level Laser Diodes in Individuals Undergoing Rhinoplasty at a Single Centre: Protocol for a Randomized, Double-blind, Controlled Clinical Trial","Inclusion criteria:\n\n* individuals 18-60 years of age;\n* ASA I or II; no comorbidities (no pre-existing diseases);\n* indication for rhinoplasty;\n* regardless of gender identity.\n\nExclusion criteria:\n\n* use of anticoagulant,\n* anti-inflammatory, or corticosteroid medications;\n* indication for closed rhinoplasty;\n* procedures not performed using the Piezo device (Schuster SW Surgery II);\n* intraoperative complications (e.g., haemorrhage or technical difficulties);\n* prior nasal filler with hyaluronic acid;\n* use of vitamin A derivatives (oral isotretinoin or topical retinoic acid) within 30 days before surgery;\n* or known allergy to any mandatory intra- or postoperative medication.","60 Years",{"count":52,"type":22},[25],"This single-centre, randomized, double-blind, sham-controlled clinical trial evaluates whether preoperative photobiomodulation (PBM) with red and infrared light can reduce early postoperative periorbital edema in patients undergoing primary open rhinoplasty with osteotomies. Sixty participants will be randomly assigned to receive active PBM or sham PBM one hour before surgery. The primary outcome is periorbital edema on postoperative day 3 measured using a validated ordinal clinical scale with standardized photographic documentation. Secondary outcomes include ecchymosis, postoperative pain, analgesic consumption, nasal tip skin thickness, and patient-reported functional and aesthetic outcomes. Participants will be followed for up to 12 months after surgery.",[333,334],"Rhinoplasty","Edema",[336,337,338,339],"Photobiomodulation","Low-Level Laser Therapy","Postoperative","Inflammation","2026-03-19",{"date":342,"type":33},"2026-03-24",{"date":344,"type":33},"2026-01-30",{"date":346,"type":22},"2030-11-30",{"name":39,"class":40},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":120,"sex":17,"minAge":143,"maxAge":279,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":73},"100625768","home-based-photobiomodulation-effects-in-the-postoperative-period-of-distal-radius-fractures-100625768","NCT07426926","Home-Based Photobiomodulation Effects in the Postoperative Period of Distal Radius Fractures","Home-Based Photobiomodulation Effects in the Postoperative Period of Distal Radius Fractures: A Double-Blind, Randomized, Controlled Clinical Trial","Inclusion criteria:\n\n* Adults aged 18 to 65 years,\n* Both sexes,\n* Patients with isolated, closed distal radius fractures with displacement and surgical indication,\n* Surgical indication defined by instability criteria:\n* Dorsal tilt of the distal fragment \\>20°,\n* Radial shortening ≥10 mm,\n* Articular incongruity,\n* Dorsal comminution,\n* Fractures classified as Fernandez types I, II, or III,\n* Fractures classified as AO\u002FOTA types 2R3A2, 2R3A3, 2R3B, or 2R3C (except 2R3C3).\n\nExclusion criteria:\n\n* Previous wrist injuries, sequelae, or motor deficits due to neurological lesions,\n* Pathological fractures,\n* Ipsilateral fractures in other regions of the limb,\n* Neurovascular injury with sensory deficit at the fracture site,\n* Local or systemic contraindications to surgery or postoperative recovery,\n* History of photosensitivity,\n* Neurological and\u002For psychiatric disorders,\n* Proliferative or infectious skin lesions at the wrist region,\n* Pregnancy,\n* Surgical complications (neurological or vascular injuries, or fracture line extension) - excluded from analysis but reported.",{"count":356,"type":22},42,[25],"This double-blind, randomized controlled clinical trial aims to evaluate the adjuvant effect of home-based photobiomodulation (PBM) therapy on the rehabilitation of surgically treated DRFs combined with an unsupervised home exercise program. A total of 42 participants will be randomly allocated into two groups. The Control Group will undergo the standard surgical procedure, perform the prescribed home exercises recommended by the hospital service, and use an inactive LED plate (photobiomodulation device). The PBM Group will follow the same surgical and exercise protocols but will use an active PBM device. Home exercises will begin 24 hours after surgery and should be performed twice daily for a total of 12 weeks. The device will be applied once daily to the wrist for 12 minutes (6 minutes on the dorsal side and 6 minutes on the palmar side). The primary outcome will be functional wrist assessment using the QuickDASH (Quick Disabilities of the Arm, Shoulder, and Hand) questionnaire at 2 weeks. Secondary outcomes will include wrist range of motion, grip strength, wrist function, and pain (assessed using the PRWE-BR instrument), as well as fracture healing. Assessments will be performed at 2, 4, 6, and 12 weeks post-surgery, except for bone consolidation (assessed starting at week 4) and for pain and range of motion, which will also be evaluated at 24 hours.",[360],"Distal Radius Fracture",[161,362,363,364],"distal radius","locked volar plate","early mobility",{"date":366,"type":33},"2026-02-23",{"date":368,"type":33},"2025-07-01",{"date":370,"type":22},"2026-12-30",{"name":39,"class":40},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":73},"100528994","exercise-training-using-an-app-on-physical-cardiovascular-function-individuals-with-post-covid-19-syndrome-100528994","NCT06168006","Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome","Effects of a Physical Training Program Using a Mobile App on the Functionality and Cardiovascular Function of Individuals With Post-covid-19 Syndrome: Randomized Clinical Trial","Recovery","Inclusion Criteria:\n\n* Laboratory diagnosis of COVID-19\n* Fatigue ≥ 8 points on the Chalder Scale and\u002For dyspnea 2-4 on the Modified Medical Research Council\n* Have access to a smartphone\n* Have no contraindications for exercise practice\n* Have ability to sit and stand and maintain balance while standing\n* Have preserved cognitive function\n* Have no risk of falls according to the Morse Fall Scale",{"count":52,"type":22},[25],"The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).",[384],"Post-Acute COVID-19 Syndrome",[386,387,388,389],"exercise","mobile app","physical function","cardiovascular function","2026-02-16",{"date":392,"type":33},"2026-02-17",{"date":394,"type":33},"2024-03-01",{"date":396,"type":22},"2026-06-30",{"name":39,"class":40},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":120,"sex":202,"minAge":143,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":73},"100591774","photobiomodulation-on-pain-perception-during-the-insertion-of-the-t-380-copper-intrauterine-device-iud-100591774","NCT06984796","Photobiomodulation on Pain Perception During the Insertion of the T 380 Copper Intrauterine Device (IUD)","Effect of Photobiomodulation on Reducing Pain Perception During the Insertion of the T 380 Copper Intrauterine Device (IUD) for Contraception: a Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Women aged 18-50 years,\n* Female,\n* No preference regarding race or socioeconomic status,\n* Nulliparous or multiparous.\n\nExclusion Criteria:\n\n* Known or suspected pregnancy,\n* Diagnosed with chronic pain,\n* Active local infection,\n* Use of any pain medication in the last 12 hours,\n* Known contraindication for IUD insertion, including significant uterine cavity distortion, active pelvic inflammatory disease, or Wilson's disease,\n* Allergy to copper,\n* Unexplained abnormal uterine bleeding,\n* Any condition affecting the lumbar region, such as active neoplasms, established osteomyelitis, or any pre-existing deep tissue lesions with necrosis or infection,\n* History of photosensitivity.","50 Years",{"count":260,"type":22},[25],"Unplanned pregnancy affects up to 65% of women in some regions of Brazil, contributing to unsafe abortions and maternal mortality. The copper IUD is an effective long-term contraceptive but is underused, with only 4.4% of women of reproductive age using it. One barrier is the pain during insertion, leading to low adherence. Photobiomodulation (PBM), which has anti-inflammatory and analgesic effects, may offer a solution. This study aims to assess PBM's efficacy as a preemptive analgesic during copper IUD insertion in a randomized, double-blind trial involving 72 participants. The experimental group (n=36) will receive active PBM, while the control group (n=36) will receive PBM simulation. Pain will be measured using the Visual Analog Scale (VAS) at multiple time points, and additional outcomes include analgesic use, quality of life (WHOQOL-100), anxiety (GAD-7), satisfaction, and adverse effects. Statistical analysis will include tests such as the Friedman test, logistic regression, and ANOVA, with a significance level of 5%.",[410],"Pain",[412,161],"intrauterine device","2026-02-03",{"date":415,"type":33},"2026-02-04",{"date":417,"type":22},"2026-03-30",{"date":419,"type":22},"2027-05-30",{"name":39,"class":40},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":73},"100593472","effects-of-a-yoga-program-on-the-functionality-of-individuals-100593472","NCT07006883","Effects of a Yoga Program on the Functionality of Individuals","Effects of a Yoga Program on the Functionality of Individuals With Knee Osteoarthritis","Inclusion Criteria:\n\n* A clinical diagnosis of knee osteoarthritis (knee pain for \\> 3 months)\n* Morning stiffness \\\u003C30 minutes\n* Crepitus\n* Bone tenderness, and absence of palpable heat and\u002For diagnosis established radiographically (determined by Kellgren and Lawrence grade 1 to 3 on a scale 1 up to 4)\n\nExclusion Criteria:\n\n* Bilateral hip or KOA\n* Severe osteoporosis\n* Fibromyalgia\n* Clinical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout), undergoing any joint replacement of the lower extremity\n* Neurological diseases (Parkinson's disease, Stroke, Multiple Sclerosis, muscular dystrophies, neuromotor disease, Alzheimer's disease)\n* Infected wounds or osteomyelitis in the knee region\n* Deep vein thrombosis or thrombophlebitis, sensory changes in the lower limbs\n* A cognitive and cardiopulmonary impairment that may prevent or limit the performance of exercises\n* Use of a walking assistance device, history of recent trauma to the knee\n* Be performing or having prior any form of treatment involving physiotherapy, intra-articular corticosteroids, anti-inflammatories, opioid medication, or chondroprotective in the six months before the start of interventions",{"count":21,"type":22},[25],"There is a notable and emerging use of structured exercise programs incorporating Yoga for chronic musculoskeletal pain. However, regarding knee osteoarthritis (KOA), the effectiveness of Yoga remains uncertain to justify its inclusion in therapeutic exercise programs in routine clinical practice. Therefore, the aim of this project is to evaluate the effects of Yoga on functionality in individuals with KOA.\n\nFor this purpose, participants with KOA, including individuals of both sexes, aged 45 years or older, with a clinical diagnosis of KOA, will be randomly allocated using a random sequence generated by software, organized in six blocks of 24 codes, with an allocation ratio of 1:1, numbered sequentially from 1 to 126. Allocation will be concealed and performed after pre-intervention assessment and confirmation of eligibility criteria. Participants will be distributed into two groups: (1) Experimental group - Yoga (n = 45) and (2) Control group - therapeutic exercise (n = 45).\n\nThe intervention will last 8 weeks, with assessments conducted at baseline, after 4 weeks, and after 8 weeks of the intervention programs. The following outcome measures will be used: Knee Injury and Osteoarthritis Outcome Score (KOOS), Berg Balance Scale (BBS), Numeric Pain Rating Scale (NPRS), Pain Self-Efficacy Questionnaire (PSEQ), Global Perceived Effect Scale (GPE), 30-Second Sit-to-Stand Test (30s-STS), Timed Up and Go Test (TUG), and Maximal Voluntary Isometric Contraction (MVIC).\n\nData analysis will include a normality test to verify the distribution of the data, followed by the appropriate statistical tests for intra- and intergroup comparisons. The comparisons will consider two factors: time and group. A significance level of 5% (p \\\u003C 0.05) will be adopted for all analyses.",[432],"Knee Osteoarthritis","2025-12-11",{"date":435,"type":33},"2025-12-18",{"date":437,"type":33},"2025-08-01",{"date":439,"type":22},"2029-01-30",{"name":39,"class":40},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":181,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":73},"100604598","efficacy-of-combined-fractional-erglass-and-thulium-lasers-versus-microneedling-for-atrophic-acne-scars-100604598","NCT07151599","Efficacy of Combined Fractional Er:Glass and Thulium Lasers Versus Microneedling for Atrophic Acne Scars","Randomized Controlled Trial Comparing Fractional Erbium:Glass (1540-1550 nm) and Thulium (1927 nm) Lasers Versus Microneedling for the Treatment of Atrophic Acne Scars","Inclusion Criteria:\n\n* Fitzpatrick skin phototypes I to VI\n* Presence of atrophic acne scars on the face\n\nExclusion Criteria:\n\n* Decompensated systemic diseases\n* Any active infection (e.g., viral such as herpes, bacterial, or fungal)\n* Pregnant or breastfeeding women\n* Presence of hypertrophic or keloid scars\n* Current use of anticoagulant or antiplatelet medications\n* History of hemophilia or coagulation disorders\n* Current use of anti-inflammatory drugs or corticosteroids\n* Use of retinoids, including isotretinoin, within the past 6 months\n* Exposure to sunlight within the past 15 days\n* Undergoing any aesthetic facial treatment or having undergone scar treatments in the facial region within 180 days prior to study initiation\n* Presence of active acne (occasional isolated lesions will not be considered exclusion criteria)",{"count":449,"type":22},84,[25],"The purpose of this study is to compare two treatments for acne scars on the face. The study will test whether fractional lasers (Erbium:Glass and Thulium) lead to better improvement in acne scars than microneedling.",[453],"Acne Scars",[455,456,457,458,453],"Fractionated Erbium Glass Laser","Fractionated Thulium Laser","Microneedling","Percutaneous Induction of Collagen","2025-11-24",{"date":461,"type":33},"2025-11-26",{"date":463,"type":33},"2025-10-16",{"date":465,"type":22},"2026-07",{"name":39,"class":40},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":474,"enrollmentInfo":475,"targetDuration":4,"studyType":477,"phases":4,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":491,"locationsCount":4},"100606406","halitosis-sleep-and-mental-health-in-bariatric-surgery-candidates-100606406","NCT07175142","Halitosis, Sleep and Mental Health in Bariatric Surgery Candidates","Assessment of Psychological Distress, Sleep Quality, and Halitosis in Patients With Obesity: Protocol for an Observational Study in the Preoperative Period of Bariatric Surgery","Inclusion Criteria:\n\n* Adults ≥18 years with a diagnosis of obesity\n* Referred for psychological care at the \"Rosinha Viegas\" Interprofessional Outpatient Clinic during preoperative preparation for bariatric surgery (Brazilian public health system - SUS)\n\nExclusion Criteria:\n\n* Individuals with cognitive or neurological limitations that impair understanding or participation in the assessment procedures\n\nIndividuals who refuse or withdraw consent","90 Years",{"count":476,"type":22},110,"OBSERVATIONAL","This study aims to evaluate psychological distress, sleep quality, and halitosis in obese patients during the preoperative period of bariatric surgery. A total of 110 adults will be assessed using validated questionnaires and a portable halitosis detector. The results may contribute to improving strategies for comprehensive care in this population.",[480,481,482,483,484],"Obesity","Bariatric Surgery Candidate","Halitosis","Sleep Disorder","Stress, Psychological","2025-09-09",{"date":487,"type":33},"2025-09-16",{"date":489,"type":22},"2025-10-01",{"date":396,"type":22},{"name":39,"class":40},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":328,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":515,"locationsCount":4},"100595731","effect-of-oculomotor-therapy-in-individuals-with-convergence-insufficiency-100595731","NCT07036263","Effect of Oculomotor Therapy in Individuals With Convergence Insufficiency","\"Effect of Oculomotor Therapy in Individuals With Convergence Insufficiency: A Blind Randomized Clinical Trial\"","Inclusion Criteria:\n\n* Individuals diagnosed with convergence insufficiency (CI);\n* Aged between 18 and 60 years;\n* Physically active individuals;\n* Without cognitive impairments;\n* Without vestibular system impairments (e.g., dizziness).\n\nExclusion Criteria:\n\n* Diagnosis of neurodegenerative diseases (e.g., Parkinson's, ALS);\n* Presence of dementia;\n* History of stroke;\n* Presence of vestibular disorders;\n* Systemic neuromuscular diseases;\n* Disabling musculoskeletal pain;\n* Diagnosis of diabetic polyneuropathy;\n* Use of joint prostheses;\n* Ongoing physical therapy treatment;\n* Lack of physical ability to perform the prescribed physical activities.",{"count":500,"type":22},70,[25],"The aim of this study is to investigate the effect of oculomotor therapy in individuals with ocular convergence insufficiency.",[504],"Convergence Insufficiency",[506,507,508],"Convergence insufficiency","Postural control","Clinical trial","2025-06-23",{"date":511,"type":33},"2025-06-25",{"date":437,"type":22},{"date":514,"type":22},"2025-12-30",{"name":39,"class":40},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":4},"100595365","effects-of-photobiomodulation-with-superpulsed-laser-and-dual-wavelengths-in-children-and-adolescents-100595365","NCT07031505","Effects of Photobiomodulation With Superpulsed Laser and Dual Wavelengths in Children and Adolescents","Effects of Photobiomodulation With Superpulsed Laser and Dual Wavelength (810 + 980 NM) in Children and Adolescents With Facial Muscle Pain and Headache: Protocol for a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Children and adolescents 6 to 17 years of age enrolled at the medical and dental clinic of Universidade Nove de Julho (UNINOVE), Vergueiro Campus;\n* Children and adolescents who present with at least one symptom of orofacial pain and\u002For headache, according to the Faces Pain Scale and the childhood and adolescence headache questionnaire based on the ICHD-3\n\nExclusion Criteria:\n\n* Pregnant adolescents;\n* Having taken corticoids, non-steroidal anti-inflammatory drugs or analgesics in the previous 30 days;\n* Having taken isotretinoin;\n* Individuals who report photosensitivity to laser or LED in previous treatments.",{"count":52,"type":22},[25],"This randomized clinical trial evaluates the effects of photobiomodulation with a superpulsed diode laser (810 + 980 nm) on orofacial pain and tension-type headache in children and adolescents. Sixty participants will be assigned to receive active PBM or sham therapy over eight sessions. Pain and anthropometric variables will be assessed.",[527,528],"Facial Pain","Headache","2025-06-12",{"date":531,"type":33},"2025-06-22",{"date":368,"type":22},{"date":534,"type":22},"2026-04-30",{"name":39,"class":40},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":203,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":73},"100502018","phase-2-photobiomodulation-in-chronic-knee-pain-in-patients-who-are-in-prerehabilitation-for-bariatric-surgery-100502018","NCT05816798","Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery","Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery: Double Blind, Randomized, Controlled Placebo Clinical Trial","Inclusion Criteria:\n\n* Obese patients with indication for bariatric surgery performed in routine follow-up at the Gastric Surgery Outpatient Clinic of HC-UFG;\n* Patients with chronic pain (\\> 3 months) in the knees bilaterally. Patients will be asked in the initial evaluation if they feel pain located in the topography of the knees that has been compromising their functionality both in daily activities and at work, and that lasts for more than or equal to 3 months. This pain may be reported as continuous or intermittent;\n* Sign the Informed Consent Term approved by the HC-UFG Ethics Committee.\n\nExclusion Criteria:\n\n* \\- Loss of follow-up in the outpatient clinic of origin and in the Physiotherapy sector, even though the use of laser therapy was maintained according to the study protocol;\n* Any reported adverse effects from the use of FBM reported;\n* Patients in whom there are changes in the medications being used for chronic pain during the study protocol will be excluded from this study. Minimal changes in the dosages of medications already in use can be tolerated, as long as there are no changes in the type of medication, but only in the prescribed dose. These modifications throughout the study, if they occur, will be described.\n* Death\n* Withdrawal of the informed consent by the participant\n* If the patient, for any reason, is excluded from the indication of bariatric surgery\n* Emergence during the study of any of the non-inclusion criteria, like: .\n* Patients with other rheumatologic diseases and\u002For systemic inflammatory diseases (rheumatoid arthritis, Reiter's arthritis, ankylosing spondylitis, generalized polyarthritis) or previous musculoskeletal diseases in the knees;\n* Clinical manifestations or complaints of knee arthralgia related to diseases other than obesity.\n* Previous use in the last 90 days of treatment with the use of Phototherapy for the same or another indication;\n* Clinical signs of neuropathy, including radiculopathies and peripheral nerve injuries;\n* Pain in the lower limb, originating from the lumbar spine (lombosciatalgia)\n* Use of corticosteroids at an immunosuppressive dose (20mg daily of prednisone or equivalent for at least 14 days);\n* Infection or tumor at the site of therapy application;\n* Current chronic infections such as tuberculosis or chronic hepatitis treated or not.\n* Blood clotting disorders (including thrombosis) at the application site.\n* Diagnosis of fibromyalgia;\n* Serious psychiatric disorders that require psychiatric care;\n* Systemic injections and\u002For joint injections of corticosteroids or hyaluronic acid during the last 48 hours prior to the initial assessment of the study;\n* Psychoaffective disorder that compromises adherence to treatment;\n* Any history of sensitivity to light or phototherapies.",{"count":544,"type":22},62,[546,547],"PHASE2","PHASE3","Chronic pain is a global public health problem, which intensifies even more in the obese population, reaching about 33% of these patients. Among the topography, chronic knee pain affects 80%, constituting an important cause of disability and decreased quality of life. In addition, in grade 3 obesity, also called morbid obesity, in which bariatric surgery is already indicated, knee pain makes it difficult or prevents participation in the pre-habilitation program that includes physical therapy through therapeutic exercises with the aim of reducing postoperative complications. In this sense, a double-blind, randomized, placebo-controlled clinical trial will be conducted with the objective of evaluating the effect of photobiomodulation (PBM) on pain and functionality of obese patients with chronic knee pain who are in a prehabilitation program for bariatric surgery, discussing its role as an analgesic therapy and modifier of peripheral and central sensitization mechanisms of the pain pathway. PBM is a safe treatment option, with no undesirable effects and low cost. The primary outcomes will be pain intensity, through visual analogue scale, and Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire, validated version for Portuguese - Brazil. Secondary outcomes will be pressure pain threshold and rolling pinch maneuver measured by digital algometer. Other exploratory outcomes will be 6-minute walk test, knee range of motion, SF-36 quality of life questionnaire. There will be 2 groups: an intervention group (photobiomodulation associated with standard physiotherapy treatment) and another placebo group (device turned off associated with the same standard physiotherapy treatment). The application sites will be knees and lumbar paravertebral 2 times a week for 12 weeks. The dosimetric standards will be 4J\u002Fpoint in the knees and 3J\u002Fpoint in the lumbar. The results obtained will be statistically analyzed and later published in a scientific journal.",[550,551],"Chronic Knee Pain","Obesity, Morbid",[336,553,554,555,556],"Chronic knee pain","Obesity Morbid","Central and periferic sensitivity","Nociception","2025-06-02",{"date":559,"type":33},"2025-06-06",{"date":561,"type":33},"2023-07-28",{"date":563,"type":22},"2026-02",{"name":39,"class":40},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":120,"sex":571,"minAge":143,"maxAge":572,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":73},"100588252","human-tecar-on-exercise-preconditioning-and-post-exercise-recovery-100588252","NCT06938984","Human TECAR on Exercise Preconditioning and Post-exercise Recovery","Inclusion Criteria:\n\n* Physically active male participants;\n* Do not present a history of musculoskeletal injury in the regions of the hips, knees and calves in the month preceding the study;\n* Are not using pharmacological agents;\n* Voluntarily commit to participate in all stages of the study.\n\nExclusion Criteria:\n\n* Present musculoskeletal or joint injuries during data collection;\n* Present history of musculoskeletal injury in the regions of the hips, knees and calves in the month preceding the study.","MALE","35 Years",{"count":574,"type":22},50,[25],"TECAR therapy (Transfer of Energy Capacitive and Resistive) is a type of diathermy that uses radiant energy to generate endogenous heat. However, to the date there are no studies investigating the effects of TECAR therapy on exercise preconditioning and post-exercise recovery in humans. Therefore, the aim of this project is to assess the effects of different treatment protocols of TECAR therapy on. exercise preconditioning and post-exercise recovery in humans",[578],"Exercise Recovery",[580,581,582],"TECAR therapy","Post-exercise recovery","Preconditioning","2025-05-06",{"date":585,"type":33},"2025-05-11",{"date":587,"type":33},"2025-04-23",{"date":589,"type":22},"2025-05-30",{"name":39,"class":40},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":120,"sex":17,"minAge":143,"maxAge":203,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":73},"100511120","effect-of-photobiomodulation-to-reduce-post-operative-pain-after-endodontic-surgery-100511120","NCT05935306","Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery","Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery: a Randomized Controlled Clinical Trial","Inclusion Criteria\n\n:• Patients with periapical lesions who have already undergone endodontic treatment (lesions smaller than 10mm in their greatest diameter - Metin et al., 2018, single and chronic lesions)\n\n* Patients with not comorbidities,\n* Age from 18 to 70 years,\n* Both genders,\n* Healthy permanent teeth with good hygiene.\n\nExclusion Criteria:\n\n* Who are taking drugs that affect bone metabolism and the inflammatory process (for example: corticosteroids, bisphosphonates),\n* Smokers, pregnant or lactating women,\n* Who used anti-inflammatory drugs in the last 3 months before surgery.\n* Who for any reason interrupted the evolution of the treatment for not attending joint appointments.\n* Patients who do not follow the guidelines or have an injury in the acute phase (pain, edema, exudate)",{"count":599,"type":22},34,[25],"The objective of this study will be to evaluate if photobiomodulation (FBM) can reduce postoperative pain in patients who will undergo endodontic surgery. For this randomized, controlled and double-blind clinical study, 34 patients without comorbidities who need endodontic surgery in the upper jaw (15 to 25 teeth) will be recruited. They will be randomly divided into an experimental group (n = 17) photobiomodulation (808nm, 100 mW, and 4J\u002Fcm2 with 5 points per vestibular). Applications will be made in the immediate postoperative period and 24 hours after surgery. Control group (n = 17) a FBM simulation will be performed in the same way as in the experimental group. In this group, the required analgesia will be administered within the standard with ibuprofen. Both groups will perform the necessary conventional procedures considered the gold standard in the literature. Both the patient and the evaluator will be blinded to the intervention performed. The primary outcome variable of the study will be postoperative pain, which will be assessed using the visual analog scale at all postoperative control visits (baseline, 24 hours and 7 days). As for the secondary outcome variables, the amount of systemic medication received according to the patient's need (will be provided by the investigator).. Radiographic images will be obtained after 1 and 2 months for evaluation of the repair (dimensions of the lesion, radiopacity). These radiographs will be taken digitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft tissues in the anterior portion of the intra and extra-oral maxilla will also be evaluated. In addition, a digital thermometer. These parameters will be evaluated 24 hours and 7 days after the intervention. The X-rays will be taken in the 1st and 3rd month respectively.",[336,603,410,339,604],"Endodontic Disease","Surgery","2025-05-03",{"date":607,"type":33},"2025-05-07",{"date":609,"type":33},"2024-06-30",{"date":611,"type":22},"2025-12-01",{"name":39,"class":40},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":328,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":631,"locationsCount":73},"100560943","phase-1-comparative-study-between-photodynamic-therapy-with-led-associated-with-probiotics-in-the-treatment-of-halitosis-100560943","NCT06583720","Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis","Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis - Controlled Randomized Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of halitosis showing sulfhydride (SH2) ≥ 112 ppb in gas chromatography.\n\nExclusion Criteria:\n\n* Individuals with dentofacial anomalies (such as cleft lip, cleft palate and nasopalatine);\n* Undergoing orthodontic and\u002For orthopedic treatment;\n* Undergoing oncological treatment;\n* With systemic alterations (gastrointestinal, renal, hepatic)\n* Undergoing antibiotic treatment up to 1 month before the research;\n* Pregnant women.",{"count":103,"type":22},[622],"PHASE1","Halitosis is a term that defines any odor or bad smell coming from the oral cavity, which can have a local or systemic origin. This project aims to verify if there is a difference in the effectiveness of treatment with antimicrobial photodynamic therapy (aPDT) with LED associated with treatment using probiotics in reducing halitosis. 92 participants, aged 18 to 60 years, diagnosed with halitosis, presenting sulfhydride (SH2) ≥ 112 ppb in gas chromatography will be selected. Participants will be randomly divided into 4 groups (n=23), which will receive different treatments: Group 1 (control): brushing, dental floss and tongue scraper; Group 2: brushing, dental floss, tongue scraper and aPDT with blue LED and annatto; Group 3: brushing, dental flossing, tongue scraper and aPDT with blue LED, annatto and probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®); Group 4: brushing, dental flossing, tongue scraper and probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®). The results of the halimetry will be compared before, immediately after the treatments, thirty days after and sixty days after. The microbiological analysis will be performed by counting the colony forming unit of viable bacteria in the tongue coating at these same times. The microbiome analysis will be performed before, thirty days after and sixty days after the treatments after DNA extraction. All groups will be treated with oral hygiene instructions with a toothbrush, toothpaste and dental floss as well as receiving material for this practice. The normality of the data will be measured by the Shapiro-Wilk test, and in the case of normality the Analysis of Variance (ANOVA) test will be applied, and in the case of non-parametric data, the Kruskal-Wallis test will be used. The Wilcoxon test will be used to analyze the results of each treatment in the two study periods.",[482],"2025-03-25",{"date":627,"type":33},"2025-03-30",{"date":629,"type":33},"2024-11-01",{"date":514,"type":22},{"name":39,"class":40},""]